Aug 7, 2019   SOURCE: PR NewsWire

$125+ Billion Pharmaceutical Contract Development and Manufacturing Market, 2024

DUBLIN, Aug. 7, 2019 /PRNewswire/ -- The "Pharmaceutical Contract Development and Manufacturing Market by Service (Pharmaceutical, Biologics, Active Pharma Ingredients, Tablet, Capsule, Parenteral, Oral Liquid), End User - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The global pharmaceutical contract development and manufacturing market is projected to reach USD 126.63 billion by 2024 from USD 90 billion in 2019, at a CAGR of 7.1% during the forecast period.

Growth in this market is driven by the rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. Also, the increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are expected to offer opportunities for market growth in the coming years.

A pharmaceutical contract development and manufacturing organization (CDMO) serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services, such as drug development and manufacturing. CDMOs provide manufacturing services for both Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDFs).

These organizations strategize new ways to cut down the cost of drug manufacturing. Pharmaceutical players are increasingly depending on contract manufacturing services to meet their fundamental needs and specified competencies while fulfilling the stringent regulations.

The prominent players in this market are Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), LonzaGroup Ltd. (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMARHealth Care Services (France), AbbVie Inc. (US), Aenova Group (Germany), Consort Medical plc (UK), AlmacGroup (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), and Evonik Industries AG (Germany).

Major market players are increasingly focusing on strategic expansions, acquisitions & mergers, and partnerships with the aim of expanding their manufacturing capabilities and increasing their market presence.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Pharmaceutical Contract Development and Manufacturing: Market Overview
4.2 Pharmaceutical Contract Development and Manufacturing Market: Geographic Growth Opportunities
4.3 Regional Mix: Pharmaceutical Contract Development and Manufacturing Market (2019-2024)
4.4 Pharmaceutical Contract Development and Manufacturing Market: Developed vs. Developing Markets, 2019 vs. 2024

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Demand for Generics
5.2.1.2 Increasing Investments in Pharmaceutical R&D
5.2.1.3 Investments in Advanced Manufacturing Technologies By Cdmos
5.2.2 Opportunities
5.2.2.1 Increasing Demand for Biological therapies
5.2.2.2 Growing Focus on Specialty Medicines
5.2.2.3 Growth in the Nuclear Medicine Sector
5.2.2.4 Growing Demand for Cell and Gene therapies
5.2.3 Challenges
5.2.3.1 Introduction of Serialization
5.2.3.2 Changing Trade Policies Between Countries
5.2.4 Trends
5.2.4.1 Increasing Cdmo Manufacturing Footprint in Asian Countries
5.2.4.2 Cdmo Industry Consolidation
5.2.4.3 Increasing Outsourcing of Clinical Trials to Emerging Markets

6 Pharmaceutical Contract Development and Manufacturing Market, By Service
6.1 Introduction
6.2 Pharmaceutical Manufacturing Services
6.2.1 Pharmaceutical Api Manufacturing Services
6.2.1.1 Need to Cut Costs and Ensure Focus on Core Areas Leads Companies to Outsource Api Manufacturing
6.2.2 Pharmaceutical FDF Manufacturing Services
6.2.2.1 Parenteral/Injectable Manufacturing Services
6.2.2.1.1 Need for High Levels of Expertise and Growing Drug Development Activity are Driving the Demand for Contract Manufacturing
6.2.2.2 Tablet Manufacturing Services
6.2.2.2.1 Shifting Manufacturing Requirements and Need to Streamline Production Processes Is Driving Market Growth
6.2.2.3 Capsule Manufacturing Services
6.2.2.3.1 Growth in Demand for Capsule Formulations has Ensured Growth Opportunities for Service Providers
6.2.2.4 Oral Liquid Manufacturing Services
6.2.2.4.1 Complexities Involved in Oral Liquid Manufacturing Have Prompted Companies to Look to Outsourcing
6.2.2.5 Other Formulations
6.3 Drug Development Services
6.3.1 Drug Substance Complexity and High Costs Have Supported the Outsourcing of Drug Development
6.4 Biologics Manufacturing Services
6.4.1 Biologics Api Manufacturing Services
6.4.1.1 The Market for Biologics Api Manufacturing Is Still in the Emergent Phase
6.4.2 Biologics FDF Manufacturing Services
6.4.2.1 Increasing R&D Costs and Process Complexity Have Prompted the Shift Toward Contract Manufacturing

7 Pharmaceutical Contract Development and Manufacturing Market, By End User
7.1 Introduction
7.2 Big Pharma
7.2.1 Emergence of New Medicines and therapy Forms to Contribute to the Growth of This Market
7.3 Small & Mid-Size Pharma
7.3.1 Growing Development of Biologic Drugs and High Pricing Pressure to Boost Market Growth
7.4 Generic Pharmaceutical Companies
7.4.1 Growing Demand for Generics to Support Market Growth
7.5 Other End Users

8 Pharmaceutical Contract Development and Manufacturing Market, By Region

Companies Mentioned 

    --  Abbvie Inc.
    --  Aenova Group
    --  Almac Group
    --  Boehringer Ingelheim International GmbH
    --  Catalent, Inc.
    --  Consort Medical Plc
    --  Evonik Industries AG
    --  Famar Health Care Services
    --  Lonza Group Ltd
    --  Recipharm AB
    --  Siegfried Holding AG
    --  Thermo Fisher Scientific Inc.
    --  Vetter Pharma International GmbH

For more information about this report visit https://www.researchandmarkets.com/r/t80kko

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/125-billion-pharmaceutical-contract-development-and-manufacturing-market-2024-300897927.html

SOURCE Research and Markets